Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 53%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is a strong company with a diverse portfolio of products in key therapeutic areas such as oncology, cardiometabolic, and immunology, providing a solid foundation for future revenue growth. The recent negative news regarding an adverse event reported to FDA's FAERS database is seen as temporary and unrelated to one of its key drugs, Foundayo. With strong projected revenue and EPS growth over the next few years, Eli Lilly presents a compelling investment opportunity for investors seeking exposure to the pharmaceutical industry.

Bears say

Eli Lilly is facing significant headwinds in their key products, with potential pricing pressure and competition in the cardiometabolic market from Tirzepatide and Forglipron. The outlook for their oncology drugs is also uncertain, with limited potential for sales growth in a highly competitive and evolving market. Furthermore, their pipeline products may not perform as expected, posing a risk to future revenue and earnings.

Eli Lilly (LLY) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 53% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 19 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Jun 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,223.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,223.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.